CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 65 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,083,425 | +34.8% | 2,285,944 | -1.0% | 0.00% | +100.0% |
| Q2 2023 | $25,277,998 | +333.3% | 2,308,493 | +245.0% | 0.00% | – |
| Q1 2023 | $5,833,994 | +37.5% | 669,036 | -1.1% | 0.00% | – |
| Q4 2022 | $4,241,944 | +258.3% | 676,546 | +100.0% | 0.00% | – |
| Q3 2022 | $1,184,000 | +10.9% | 338,273 | -6.6% | 0.00% | – |
| Q2 2022 | $1,068,000 | -74.7% | 362,120 | -73.3% | 0.00% | – |
| Q1 2022 | $4,224,000 | -6.3% | 1,358,050 | +1.8% | 0.00% | – |
| Q4 2021 | $4,509,000 | -3.3% | 1,333,890 | +4.5% | 0.00% | – |
| Q3 2021 | $4,661,000 | -21.2% | 1,276,967 | -5.9% | 0.00% | – |
| Q2 2021 | $5,917,000 | +1.0% | 1,357,224 | +5.1% | 0.00% | – |
| Q1 2021 | $5,860,000 | -43.5% | 1,290,846 | -28.6% | 0.00% | -100.0% |
| Q4 2020 | $10,380,000 | -12.6% | 1,808,347 | +10.2% | 0.00% | 0.0% |
| Q3 2020 | $11,877,000 | +140.6% | 1,640,514 | +16.0% | 0.00% | – |
| Q2 2020 | $4,937,000 | +134.6% | 1,414,471 | -0.5% | 0.00% | – |
| Q1 2020 | $2,104,000 | -23.9% | 1,421,566 | +0.8% | 0.00% | – |
| Q4 2019 | $2,763,000 | -65.9% | 1,409,914 | -10.8% | 0.00% | -100.0% |
| Q3 2019 | $8,097,000 | -29.6% | 1,581,453 | -1.5% | 0.00% | 0.0% |
| Q2 2019 | $11,501,000 | -31.5% | 1,606,334 | +27.0% | 0.00% | 0.0% |
| Q1 2019 | $16,796,000 | +66.4% | 1,264,755 | -1.4% | 0.00% | 0.0% |
| Q4 2018 | $10,092,000 | -30.7% | 1,282,395 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $14,571,000 | -17.8% | 1,315,230 | -0.5% | 0.00% | 0.0% |
| Q2 2018 | $17,734,000 | +483.7% | 1,321,563 | +465.3% | 0.00% | – |
| Q1 2018 | $3,038,000 | +642.8% | 233,790 | +425.1% | 0.00% | – |
| Q4 2017 | $409,000 | +46.6% | 44,522 | +28.3% | 0.00% | – |
| Q3 2017 | $279,000 | – | 34,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |